Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury

Gatti, Stefano; Bruno, Stefania; Deregibus, Maria Chiara; Sordi, Andrea; Cantaluppi, Vincenzo; Tetta, Ciro; Camussi, Giovanni

doi:10.1093/ndt/gfr015

Cited by 699 publications

(592 citation statements)

References 45 publications

Supporting

Mentioning

566

Contrasting

Unclassified

Order By: Relevance

“…It has been shown that a single administration of MVs derived from adult BM-MSCs immediately after induction of IRI protects rats against AKI and CKD development. 32 In this in vivo model, MVs seem to act by a mechanism …”

Section: ©2 0 1 1 L a N D E S B I O S C I E N C E D O N O T D I S Tmentioning

confidence: 84%

The role of microvesicles in tissue repair

Bruno²,

et al. 2011

View full text Add to dashboard Cite

Section: ©2 0 1 1 L a N D E S B I O S C I E N C E D O N O T D I S Tmentioning

confidence: 84%

The role of microvesicles in tissue repair

Bruno²,

et al. 2011

View full text Add to dashboard Cite

“…The regenerative capacities of microvesicles appear to be at least partly dependent on the mRNA cargo, as treatment with RNAase to inactivate the mRNA content abrogated the protective effects. 73 Some advantages of exosomes and microvesicles are that they may be more defined and with more controlled functions compared with viable cells, and that they can deliver target molecules intracellularly. 74 Microvesicles derived from MSCs were also demonstrated to inhibit tumor growth.…”

Section: Cd39 and Cd73mentioning

confidence: 99%

Stromal cells–are they really useful for GVHD?

Kaipe

Erkers

Sadeghi

et al. 2014

Bone Marrow Transplant

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs) have immunomodulatory effects and are increasingly being used for the treatment of acute and chronic GVHD. Although they seem immuno-privileged, they induce alloresponses, but the risk of immunization is poorly characterized. After infusion, they first reach the lungs, liver and spleen, and are then difficult to trace. Several mechanisms are involved in stromal cells suppressing alloreactivity, such as induction of regulatory T cells, but whether or not this will also affect leukemic relapse or increase infections is not known. Although several encouraging pilot studies have been published, there have been few prospective randomized trials. There may be a bias in the literature, as negative results are seldom published, and there have been few comparative studies with other immunosuppressive regimens. Most animal models have failed to show any effect on GVHD. Several questions remain to be answered for optimization of stromal cell therapy. Which source is optimal-BM, fat, cord or decidua? Can stromal cells be replaced by exosomes, which culture conditions are most appropriate and at what passage and how frequently should cells be administered? More research is required to move stromal cell therapy forward to become an established treatment for acute and chronic GVHD.

show abstract

“…The release of MSC-derived microvesicles (MV) and the associated transfer of MV mRNA has already been demonstrated to activate the proliferation of tubular epithelial cells and to protect against both acute and chronic kidney injury induced by I/R injury. 36,37 The release of these secretory factors by the transplanted cells and not the engraftment and differentiation of the cells is consistent with a paracrine mediated repair of the kidney. Investigation of the factors secreted by the PCs is ongoing.…”

mentioning

confidence: 52%

Pathfinder Cells Provide A Novel Therapeutic Intervention For Acute Kidney Injury

McGlynn

Eller

MacDonald

et al. 2013

Rejuvenation Research

View full text Add to dashboard Cite

Pathfinder cells (PCs) are a novel class of adult-derived cells that facilitate functional repair of host tissue. We used rat PCs to demonstrate that they enable the functional mitigation of ischemia reperfusion (I/R) injury in a mouse model of renal damage. Female C57BL/6 mice were subjected to 30 min of renal ischemia and treated with intravenous (i.v.) injection of saline (control) or male rat pancreas-derived PCs in blinded experimentation.

show abstract

Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury

Abstract: MVs released from MSCs protect from AKI induced by ischaemia reperfusion injury and from subsequent chronic renal damage. This suggest that MVs could be exploited as a potential new therapeutic approach.

Cited by 699 publications

References 45 publications

The role of microvesicles in tissue repair

The role of microvesicles in tissue repair

Stromal cells–are they really useful for GVHD?

Pathfinder Cells Provide A Novel Therapeutic Intervention For Acute Kidney Injury

Contact Info

Product

Resources

About